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Abstract
A cause of hypophosphatemia is phosphate wasting disorders. Knowledge concerning mechanisms involved in phosphate
wasting disorders has greatly increased in the last decade by the identification of phosphatonins, among them FGF-23. FGF-
23 is a primarily bone derived factor decreasing renal tubular reabsorption of phosphate and the synthesis of calcitriol. Currently,
pharmacological treatment of these disorders offers limited efficacy and is potentially associated to gastrointestinal, renal, and
parathyroid complications; therefore, efforts have been directed toward newer pharmacological strategies that target the FGF-23
pathway. This review focuses on phosphate metabolism, its main regulators, and phosphate wasting disorders in adults, highlight-
ing the main issues related to diagnosis and current and new potential treatments.
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Introduction
Phosphorus is the most abundant anion in the human body and
is essential for many biological functions. In humans, phos-
phate comprises 1% of total body weight. Eighty-five percent
of the total phosphorous pool is localized in bones and teeth,
complexed with calcium as hydroxyapatite crystals or as
amorphous calcium phosphate, and 15% in soft tissue.
Phosphate is essential for energy storage and metabolism,
nucleic acids, cell membrane function, and oxygen transport,
and it has a critical role in cell signaling, through phosphor-
ylation reactions and enzyme activation. Moreover, phos-
phate has been shown to be involved in osteopontin gene
expression, chondrocyte apoptosis, and vascular differentia-
tion [1].
Normal serum phosphate levels vary greatly between child-
hood and adulthood. During infancy, higher serum phosphate
levels are necessary for adequate bone mineralization; levels
within the adult normal range are not sufficient for children
and cause rickets [2].
For these reasons, phosphate has a key role for life, and
phosphate homeostasis must be closely regulated, since hypo-
and hyperphosphatemia can cause severe problems in various
organs and systems.
This review focuses on phosphate metabolism, its main
regulators, and phosphate wasting disorders in adults,
highlighting themain issues related to diagnosis and treatment.
Phosphate homeostasis
Under physiological conditions, a balance between intestinal
absorption, renal excretion, and influx to and efflux from bone
and soft tissues maintains an adequate phosphate homeostasis.
Vitamin D, parathyroid hormone (PTH), and fibroblast
growth factor-23 (FGF-23) are its main regulators [3].
The total plasma phosphate level is subdivided in inorganic
and organic phosphate. The concentration of inorganic
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phosphate in the plasma is between 0.80 and 1.30 mmol/l.
Equilibrium between intracellular and extracellular phosphate
is regulated by multiple factors. The pH state regulates the
relative proportion of HPO4
2− and H2PO4
−, and at normal
pH the ratio is 4:1. In acidic conditions, this ratio decreases,
whereas in alkaline states, it increases. Moreover, plasma
phosphate levels are lowest in the morning and highest at
night. Plasma phosphate can be lowered by a shift into cells
by glucose ingestion, insulin, muscle activity, and hyperven-
tilation. Depending on age, serum phosphate concentration
varies. Infants have the highest concentration of phosphate
compared with adolescents and adults. In children, there is a
positive balance of 2–3 mmol/day in order to allow adequate
growth, and in elderly subjects, there is a small negative bal-
ance, caused mainly by an age-related bone loss [1]. No gen-
der differences in phosphate concentration in the age group
20–40 years have been described; however, phosphate con-
centration is lower in older men than in women. During preg-
nancy, plasma phosphate decreases [1].
Hypophosphatemia is defined by serum phosphate concen-
tration < 0.80 mmol/L in adults and severe hypophosphatemia
in case of < 0.30mmol/L. Several causes of hypophosphatemia
have been identified [1]. Among these, phosphate wasting dis-
orders causing hypophosphatemia are described in the follow-
ing chapters.
Intestinal absorption
The human diet is usually abundant in phosphate, and the
average intake of phosphate is about 20 mg/kg/day, but the
net absorption of phosphorous is less than 900 mg or 64% of
total intake [4].
Phosphate absorption takes place throughout the small in-
testine and colon. There are two mechanisms of intestinal
phosphate absorption: an active sodium-dependent pathway
and a passive sodium-independent pathway. The passive
transport of phosphate occurs by paracellular transport via
tight junctions between cells, while the active transport occurs
via the sodium-phosphate cotransporter NPT2b and possibly
type 3 transporters PiT1 and PiT2 [1]. NPT2b is expressed in
the brush border of enterocytes and belongs to the SLC34
solute carrier family [1]. During low-phosphate intake, ab-
sorption mostly occurs actively, whereas during high phos-
phate intake, passive absorption is prevalent [1].
Two important factors that regulate intestinal phosphate
absorption are dietary phosphate intake and 1,25-
dihydroxyvitamin D3 [1,25(OH)2D3] [1]. Active transport of
phosphate is regulated by 1,25(OH)2D3, inducing the expres-
sion of NPT2b on the apical membrane of intestinal epithelial
cells, and low-phosphate diets upregulate NPT2b expression,
probably through the action of 1,25(OH)2D3, although the
detailed mechanism of this regulation remains unclear [5, 6].
Of note, FGF-23, the most important phosphatonin, with its
cofactor Klotho, reduces the expression and activity levels of
CYP27B1 (1-alpha-hydroxylase) and stimulates 24 hydroxy-
lase, which, respectively, suppresses the production and in-
creases the catabolism of active vitamin D. Therefore, reduced
1,25(OH)2D3 is associated with lower Pi absorption [1].
Renal reabsorption and excretion
In physiological conditions, the maintenance of phosphate
balance is mainly guaranteed by urinary excretion of phos-
phate. About 90% of serum phosphate is ultra-filterable, and
after glomerular filtration, the main site of phosphate reab-
sorption is the proximal convoluted tubule. The phosphate
transports in the renal tubules are the type 2 sodium-
phosphate cotransporters, NPT2a and NPT2c, encoded by
SLC34A1 and SLC34A3 genes, respectively, and, to a much
lower extent, the type 3 transporters. NPT2a and 2c are the
main transporters responsible for controlling inorganic phos-
phate reabsorption in the renal proximal tubule [1]. NPT2a has
a high affinity for phosphate, and its highest concentration is
in the brush border membrane of the S1 segment of proximal
convoluted tubule. On the other hand, NPT2c has a lower
affinity for phosphate. Both transporters, NPT2a and NPT2c,
allow the transport of phosphate into the cell, and the rate
depends on the number of transporters available and on the
sodium gradient across the luminal membrane, created by the
Na+/K+-ATPase in the basolateral membrane [1].
The regulation of renal phosphate reabsorption is complex,
and it is influenced by several factors, including dietary phos-
phate intake, hormones such as FGF-23 and PTH, and extra-
cellular fluid (ECF) volume depletion.
Variations in dietary phosphate intake change the rate of
renal phosphate reabsorption due to the changes of expres-
sion of phosphate transporters, such as NPT2a, NPT2c, and
PiT2, independently of PTH and 1,25(OH)2D3 [7].
Moreover, a study described that NaPi-2-like transporters
in the brain are regulated by both dietary phosphate and
cerebrospinal fluid phosphate concentrations and, most sig-
nificantly, that the central phosphate milieu can regulate
renal NaPi-2 expression. Therefore, a role of NPT2a, local-
ized in the brain, in the adaptive changes of phosphate re-
absorption, through central transporters in the brain acting
like phosphate sensors, is hypothesized [8].
The phosphaturic hormone FGF-23, with its cofactor
Klotho, directly downregulates membrane expression of
NPT2a by serine phosphorylation of the scaffolding protein
Na+/H+ exchange regulatory cofactor (NHERF1) via extracel-
lular signal-regulated kinase 1/2 and serum/glucocorticoid-
regulated kinase-1 signaling in proximal tubular segments
[9]. Therefore, the suppression of renal cotransporter by
FGF-23 impairs the renal reabsorption of phosphate, causing
a reduction of serum phosphate levels. In addition to FGF-23,
other “phosphatonins,” including secreted frizzled-related
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protein 4 (sFRP-4), fibroblast growth factor 7 (FGF-7), and
matrix extracellular phosphoglycoprotein (MEPE), are hor-
mones that regulate phosphate metabolism by reducing renal
phosphate reabsorption. The description of the major role of
FGF-23 will be discussed in the next chapter.
In addition to the FGF-23, the regulators of phosphate re-
absorption are mostly dietary Pi intakes and to a lesser extent
PTH, which, through interaction with PTH/PTHrP receptors
(highly expressed in renal tubules), determines an acute effect
of a rapid endocytosis and degradation of NPT2a transporters
and also seems to regulate NPT2c transporters [10].
Some studies show that 1,25(OH)2D3 stimulates phosphate
reabsorption, acting directly on the proximal tubule through the
induction of NPT2a and NPT2c, and appears to have a permis-
sive role in the action of PTH on phosphate reabsorption [11].
Lastly, in hemodialyzed patients with chronic kidney dis-
ease (CKD), the levels of sclerostin, a potent inhibitor of bone
formation, tend to be higher compared to those of control
subjects, although the pathophysiological relevance of circu-
lating levels remains undetermined. A study evaluated the
association between sclerostin and phosphate levels besides
PTH, biomarkers of bone turnover, vascular calcifications,
and mortality. In a multivariate model, a positive association
was described with phosphate, and this association was inde-
pendent of PTH and FGF-23 levels. This interesting result will
require additional research in the future [12].
Figure 1 shows phosphate metabolism and its regulators.
FGF-23 and its multisystemic actions
FGF-23 is a glycoprotein with 251 amino acids. It is primarily
secreted by osteocytes, and to a lesser extent by osteoblasts, or
venous sinusoids of the bone, endocrine organs (e.g., parathy-
roid glands, ovaries, testes), heart, hypothalamus, cortex, hip-
pocampus, caudate putamen, amygdala, and ventrolateral tha-
lamic nucleus, although the physiological relevance of FGF-
23 produced by these other tissues has not yet been determined
[13, 14]. Under physiological conditions, FGF-23 is almost
exclusively produced by osteocytes and osteoblasts in re-
sponse to high serum phosphate levels and 1,25(OH)2D3 [15].
The FGF-23 gene is located on chromosome 12p13.29. The
mature protein, FGF-23 (25-251), is secreted into circulation
upon cleavage of the signal sequence comprising 24 amino
acids and O-glycosylation by UDP-N-acetyl-alpha-D-galactos-
amine: polypeptide N-acetylgalactosaminyltransferase 3
(GALNT3) [16, 17]. The O-glycosylation occurs in the 162–
228 region of FGF-23, and this post-translational modification
protects it from cleavage by subtilisin-like proprotein
convertases when using recombinant peptides in vitro. Intact
FGF-23 is cleaved by a furin proprotein convertase into inac-
tive N- and C-terminal fragments, and FGF-23 is then removed
by the kidney. The signal peptide with 24 amino acids is in the
N-terminal portion of the FGF-23 protein, and next to the signal
peptide is the FGF homology region. Its C-terminal peptide
binds in a coordinated fashion to FGF receptors (FGFR) in
the tissue as well its cognate coligand Klotho, which exists both
as a transmembrane protein and a soluble form, the latter of
which regulates phosphorus metabolism with FGF-23 [18–20].
Receptor specificity for FGF-23 relies on its interaction
with FGF receptors (FGFR1, 3, or 4) and the coreceptor α-
Klotho, resulting in activation of the mitogen-activated pro-
tein kinase (MAPK) pathway and phospho-ERK. Both the N-
terminal and C-terminal portions of FGF-23 are necessary for
this complete interaction [18].
Regulation of FGF-23
Although the regulation of FGF-23 has been extensively ex-
amined, it has not yet been fully elucidated. However, the
main regulation of FGF-23 is based on systemic
[1,25(OH)2D3 and serum phosphate] and local factors [1, 21].
Serum phosphate and 1,25(OH)2D3 are both positive reg-
ulators of FGF-23; when serum phosphate or vitamin D levels
are high, FGF-23 level is elevated to increase renal phosphate
excretion and to decrease active 1,25(OH)2D3 levels. In par-
ticular, 1,25(OH)2D3 regulates FGF-23 via both vitamin D
receptor (VDR) dependent and independent mechanisms.
Indeed, the active form of vitamin D appears to increase
FGF-23 expression levels in vitro and in vivo by activating
the VDR [22], and FGF-23 in turn suppresses 1,25(OH)2D3
[18]. The effect of oral phosphate on FGF-23 concentration is
not fully clear [23]. It remains to be elucidated whether the
induction of FGF-23 is exerted by Pi itself or mediated
through additional factors such as PTH.
Another feature of FGF-23 is that it is regulated in a man-
ner that involves circadian rhythms, and this rhythmic profile
of FGF-23 may be influenced by the timing of food intake
driven sympathetic activation, as described in mice [24, 25].
The role of PTH in the regulation of FGF-23 has not been
fully clarified, although the FGF receptor and its cofactor
Klotho are expressed in parathyroid glands [26]. In the skele-
ton, PTH has been suggested to have a role as positive regu-
lator of the expression of FGF-23, given that, in case of high
PTH levels such as CKD and Jansen metaphyseal
chondrodysplasia, caused by a mutation in the PTH1R gene,
circulating FGF-23 levels were reportedly elevated [27].
However, the data from in vitro studies for the induction of
FGF-23 by PTH are limited, and FGF-23 levels were previ-
ously reported to be similar in patients with primary hyper-
parathyroidism and healthy controls [28]. Experimental stud-
ies have shown an inhibitory effect of FGF-23 on both PTH
production and secretion. A recent study investigated this re-
lationship using wistar rats allocated to treatment with intra-
venous recombinant FGF-23 and inhibition of the FGF recep-
tor in case of normocalcemia or acute hypocalcemia [29]. This
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study described that FGF-23 rapidly inhibited PTH secretion
in normocalcemia and that this effect was blocked by inhibi-
tion of the FGF receptor. On the other hand, in case of acute
hypocalcemia, there was no effect, when increased PTH se-
cretion is needed to restore the calcium homeostasis [29].
Regarding bone mineralization, a recent study showed that
FGF-23, in a Klotho-independent manner, is able to act
through FGF receptor-3 to regulate osteopontin secretion in-
directly by suppressing alkaline phosphatase transcription and
phosphate production in osteoblastic cells. Therefore, FGF-23,
derived by osteocytes, may form an autocrine/paracrine feed-
back loop for the local fine-tuning of bonemineralization [30].
In addition to phosphorus, 1,25(OH)2D3, and PTH, there
are several factors, produced in the bone, that have an impor-
tant role in FGF-23 regulation, encoded by phosphate regulat-
ing endopeptidase homolog X-linked (PHEX), dentin matrix
acidic phosphoprotein 1 (DMP-1), and ectonucleotide
pyrophosphatase/phosphodiesterase 1 (ENPP1) genes [31,
32]. Among these, dentin matrix acidic phosphoprotein
(DMP1), an inducer of mineralization of bone, is able to in-
hibit FGF-23, most likely through indirect mechanisms [33].
Deletion of the PHEX, highly expressed in osteocytes and
osteoblasts, leads to high FGF-23 levels, although the exact
mechanism remains unclear. On the other hand, the proteolyt-
ic cleavage of MEPE releases the C-terminal acidic serine-
aspartate-rich MEPE (ASARM) peptide, with an inhibitory
effect on mineralization and renal phosphate reabsorption
[34]. MEPE and ASARM may influence FGF-23 by decreas-
ing PHEX activity [34].
In bone, it has also been shown that FGF-23 synthesis and
catabolism are regulated by several additional factors, includ-
ing calcium, PTH, the renin-angiotensin-aldosterone system
(RAAS), oxidative stress, inflammation, and parameters of
iron metabolism as well as parenteral iron supplementation
[35, 36].
Classical and non-classical FGF-23 actions
The classical actions of FGF-23 involve the downregulation
of the activity and expression of the sodium-dependent phos-
phate transporters NPT2a and NPT2c in the proximal tubule
apical membrane, reducing the renal phosphate reabsorption
[37]. Moreover, FGF-23 inhibits 1 alpha-hydroxylase inde-
pendently of PTH, reducing the renal synthesis of
1,25(OH)2D3, as well as stimulating the 25-vitamin D-24 hy-
droxylase [37].
Non-classical actions of FGF-23 include other renal effects,
such as stimulation of distal tubular sodium and calcium reab-
sorption, suppression of the angiotensin converting enzyme-2
(ACE2) transcription in the kidney, and at the parathyroid
gland it may inhibit PTH secretion [35]. The biological effects
of C-terminal FGF-23 are not well known, but it may have
inhibitory effects on the actions of intact FGF-23 [35].
Moreover, FGF-23 levels appear to be associated with in-
creased cardiovascular comorbidity and cognitive dysfunction
in CKD patients. FGF-23 directly induces left ventricular hy-
pertrophy via activation of FGFR4/calcineurin/nuclear factor
of activated T cell (NFAT) signaling pathway in rodents and
most likely in patients with CKD. FGF-23 signaling negatively
affects neutrophil recruitment and host defense during CKD. It
directly acts on hippocampal neurons and may thereby impair
memory function and learning capacity in CKD patients [35].
In case of early CKD, a high FGF-23 serum concentration is
the first metabolic alteration detectable [35]. FGF-23 serum
concentrations rise progressively with declining renal function
and, consequently, 1,25(OH)2D3 deficit, secondary
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hyperparathyroidism, and, presumably, Klotho deficiency
[35]. These elevated FGF-23 levels tend to maintain serum
phosphate concentrations within normal limits in CKD pa-
tients until their renal function becomes markedly restricted
[35].
Other phosphatonins
The protein secreted frizzled protein4 (sFRP4) is ubiquitously
expressed and circulates as a 48-kD protein. As the expression
of this gene is increased in tumor-associated osteomalacia
(TIO), it has been suggested to be a phosphatonin. FGF-7 has
been shown to be increased in TIO, but its exact role in phos-
phate homeostasis is yet to be determined. MEPE is a 525
amino acid protein expressed in bone, salivary glands, and den-
tal tissue and expressed in tumor-associated osteomalacia [38].
FGF23 assays
Currently, several FGF-23 immunoassays are available, but
they are usually reserved for research purposes. Figure 2 shows
assay kits for measuring circulating FGF-23. They detect intact
FGF-23 (iFGF-23) or both iFGF-23 and C-terminal FGF-23
(cFGF-23) portions, and most assays are characterized by the
presence of a double antibody sandwich ELISA with colori-
metric reading. Antibodies of iFGF-23 detect epitopes within
both the amino-terminal and the C-terminal fragments, and the
cFGF-23 assay is based on antibodies detecting two different
epitopes in the C-terminal portion. In patients with different
stages of renal function, it is not yet clear if the cFGF-23 assay
provides comparable sensitivity to that for iFGF-23. The use of
only one assay may cause a significant underestimation; how-
ever, a study described that measurements obtained with iFGF-
23 and cFGF-23 assays would reflect the same circulating
moiety. Therefore, in the future, additional investigations are
needed to determine whether this applies regardless of kidney
function [39]. Recently, the performance of a new automated
assay for iFGF-23 on the DiaSorin Liaison platform, which is
approved for clinical use, has been evaluated in 908 healthy
French subjects with disorders of phosphate metabolism and in
adult patients (18–89 years) with CKD [40]. The results
showed that this new, fully automated immunoassay for
iFGF-23 available on a platform, now approved for clinical
use by the European Community authorities, had excellent
analytical characteristics. Adult reference values were
established and the expected concentrations in patients with
various disorders of phosphate metabolism and in patients with
CKD were obtained. This assay uses three monoclonal anti-
bodies: one coated on microparticles and directed against the
N-terminal portion of the iFGF-23; another, labeled with
fluoresceine, directed against the C-terminal fragment; and
the third, bound with isoluminol, directed against fluoresceine.
This assay is reserved for the measurement of iFGF-23 in
EDTA plasma. The availability of this new assay appears to
allow real improvement for the laboratories and clinicians/
researchers involved in this field [40].
Phosphate wasting disorders in adults
The causes of hypophosphatemia due phosphate wasting
are subdivided into genetic and acquired forms. The
Kainos and Immunotopics Human Intact FGF-23 ELISA Kits have antibodies directed to the N- and C-terminal (C-term) portions,
detecting only the intact molecule. Immunotopics® Human FGF-23 (C-term) ELISA kit identify only C-term fragment, detecting both
the intact molecule and carboxyl portions.
Kainos® FGF-23 ELISA kit
Immunotopics® Human Intact FGF-23 ELISA kit
Immunotopics® Human FGF-23 (C-term) ELISA kit
FGF-23: 32-kDa protein of 251 amino acids, with a leader sequence of 24 amino acids encoding for a signal peptide. There are two circukating FGF-23 forms: active and inactive
forms. The inactive forms derived from a proteolytic cleavage between Arg 179 and Ser 180, due to protein convertases during processes of secretion, generating N-terminal
and C-terminal fragments. FGF-23 assay kits: detect intact FGF-23 alone or both intact and C-terminal FGF-23 fragments. Most FGF-23 assays consisting of a double antibody
sandwich ELISA with colorimetric reading. Antibody tests detect epitopes within the amino-terminal and the carboxyl-terminal fragments. Then, the C-terminal FGF-23 assay
measures both the intact molecule and the large carboxyl terminal portion of FGF-23. Reference: [39]
FGF-23 active form
N-terminal FGF-23
15252
FGF-23 active form 15252
C-terminal25 251179 180FGF-23 active form 15252
Fig. 2 This figure illustrates epitopes recognized by the FGF-23 assays
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genetic forms, and TIO, are discussed below. Table 1
shows main features regarding etiology, biochemical
exams, and treatment of genetic phosphate wasting disor-
ders , TIO, and hypophosphatemia due to rena l
transplantation.
Moreover, among the main acquired forms of
hypophosphatemia due to phosphate wasting, there are also
hypophosphatemia related to hepatic surgery and alcohol or
drug-induced hypophosphatemia.
After hepatic surgery, hypophosphatemia is often de-
scribed. Serum phosphate levels usually reduce on the first
or second post-operative day and normalize by the ninth
day. Renal phosphate loss, independently of FGF-23,
FGF7, sFRP4, or PTH-related effects, and the uptake of
phosphate by rapidly regenerating liver cells were hypoth-
esized as possible mechanisms; however, the pathogenesis
for hypophosphatemia post-hepatic surgery is not well
known [1].
The mechanisms that cause acute and chronic
alcoholism-induced hypophosphatemia are mainly based
on increased renal phosphate loss, due to alcohol, aci-
dosis and associated magnesium depletion; reduced
phosphate intake, caused by poor diet, anorexia, gastri-
tis, vomiting and diarrhea; and, last, increased cellular
uptake for hyperventilation, intravenous glucose and bi-
carbonate, catecholamine release, and anabolic state dur-
ing recovery [1].
Lastly, some drugs, which are listed below, can cause drug-
induced hypophosphatemia, due at least partially to increased
renal phosphate loss. Sympatomimetics, dopamine, and the-
ophylline can cause hypophosphatemia by increased renal
loss of phosphate [1]. The antiviral drugs cidofovir and
adefovir can induce Fanconi syndrome [1]. Intravenous ad-
ministration of saccharated iron can cause hypophosphatemia,
due to an increase in FGF-23 for inhibition of its degradation
and, probably, a direct effect of iron on renal tubules causing
phosphate wasting [1]. Paracetamol in toxic doses can also
determine hypophosphatemia. The mechanism is due to trans-
cellular shift and an increased renal phosphate loss [1].
Moreover, other drugs can induce increased renal loss of phos-
phate, such as rapamycin, ifosfamide, anti-EGF treatment,
tyrosine kinase inhibitors (e.g., imatinib), bisphosphonate, ac-
etazolamide (carbonic anhydrase inhibitors), anticonvulsants,
diuretics, estrogens, suramin, and azacitidine [1].
X-linked hypophosphatemic rickets
Definition
X-linked hypophosphatemic rickets (XLH) is a rare inherited
form of renal phosphate wasting disorder, but among the
inherited forms, it is the most common with an estimated
prevalence of 1/20,000 [41, 42].
Cause
XLH is caused by a variety of inactivating mutations in the
PHEX gene, located on the X chromosome, which is
expressed in osteocytes and odontoblasts [43]. Indeed, this
gene encodes an endopeptidase, which is thought to degrade
FGF-23, and in XLH this endopeptidase appears to be inac-
tive; however, the exact mechanism is not well known [44].
FGF-23 was initially referred to as a substrate of PHEX, but
subsequent research found that FGF-23 is not a direct sub-
strate of PHEX [45]. PHEX protein is expressed in various
tissues, including the kidney, but is most abundant in mature
osteoblasts and odontoblasts and it is important for normal
matrix mineralization. It is now thought that it might control
mineralization by binding proteins such as DMP-1 and matrix
extracellular phosphoglycoprotein, which are both members
of the SIBLING proteins and contain ASARM peptides,
preventing their proteolysis and the release of ASARM pep-
tides, which inhibit mineralization [46]. There are over 170
different mutations in PHEX (e.g., missense, non-sense, dele-
tions, and splice site mutations); however, a clear genotype-
phenotype correlation has not been described [46]. Other ge-
netic and environmental factors may influence the clinical
manifestations of this disease. In some cases, a PHEX gene
mutation cannot be detected, and sporadic cases are common.
The XLH diagnosis is not necessarily based on genetic muta-
tion but can also be made from appropriate biochemical
studies.
Clinical expression
Rickets is the presenting clinical feature of XLH in children;
however, clinical manifestations have a wide variation in se-
verity, ranging from mild hypophosphatemia to severe bone
disease [32]. Females usually have less relevant bone involve-
ment than males, perhaps due in part to a difference in relative
gene dosage [4]. The onset of clinical manifestation is gener-
ally during late infancy. Initial clinical features of XLHmay be
recognized as a delay in walking in the first years of life and,
subsequently, short stature, reduced growth rate, and bone de-
formity [4]. Subjects with XLH can develop skeletal deformi-
ties that primarily include bowing of the long bones and wid-
ening of the metaphyseal region, more commonly at
costochondral junctions (rachitic rosary). Genua vara and
valga, coxa vara, and femoral and crural bowing are frequently
present [4]. In childhood, early pharmacological treatment of
high-dose vitamin D and phosphate supplementation may pre-
vent or at least reduce long-bone deformities and facilitate
healing of pseudofractures [4]. However, many patients, de-
spite adequate medical management, or because of delayed
diagnosis, still develop significant bone deformities (especially
of the lower extremities), requiring corrective surgical treat-
ment [4].
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In adulthood, patients tend to develop osteomalacia with
bone pain, degenerative joint disease characterized by joint
pain, stiffness, and decreased joint mobility due to
enthesopathy (calcified ligaments and teno-osseous junc-
tions), and dental disease, such as tooth decay and dental
abscesses. Enthesopathy and osteoarthritis are among the
most significant complications and complaints of adult
patients affected by XLH. The pathogenesis of enthesopathy,
craniosynostosis, and tendency for hyperparathyroidism is not
well explained [32]. However, recent pieces of evidence of
expression of FGFR and Klotho in sites where enthesopathy
develops suggest that FGF-23 could have a specific role [47].
Medical treatment can improve these abnormalities, but they
cannot be completely resolved. In particular, enthesopathy
Table 1 Main features regarding etiology, biochemical exams, and treatments of genetic phosphate wasting disorders, tumor-induced osteomalacia,
and hypophosphatemia due to renal transplantation
Disorders that are FGF-23-mediated
Disorders Abbreviation Gene Mechanism Serum calcium Urine calcium
X-linked hypophosphatemic
rickets
XLH PHEX FGF-23 increased Normal Normal/low
Autosomal dominant
hypophosphatemic rickets
ADHR FGF-23 FGF-23 increased Normal Normal/low
Autosomal recessive
hypophosphatemic rickets
ARHR DMP1/ENPP1 FGF-23 normal/increased Normal Normal/low
Tumor-induced osteomalacia TIO (Acquired) FGF-23 increased Normal Normal/low
Hypophosphatemia due to
renal transplantation
(Acquired) Increase of renal phosphate loss.
Contributing factors: high levels
of serum FGF-23 and PTH.
Tacrolimus and high-dose
steroids tend to decrease
the expression of NPT2a
Normal Normal/low
McCune-Albright GNAS1 FGF-23 increased Normal/high Normal
Disorders that are non-FGF-23-
mediated
Hereditary hypophosphatemic
rickets with hypercalciuria
HHRH SLC34A3 Proximal tubular phosphate
wasting
Normal High
Fanconi syndrome Various (SLC34A1) Impairment of function of the
proximal tubules
Variable: normal/
low/high
Normal/high
Disorders that are FGF-23-mediated
Disorders Serum PTH Serum phosphate Tmp/GFR Serum 1,25(OH)2D3 Standard treatments of
hypophosphatemia
X-linked hypophosphatemic
rickets
Normal/high Low Low Low or inappropriate Phosphate supplementation
and calcitriol or alfacalcidiol
Autosomal dominant
hypophosphatemic rickets
Normal Low Low Low or inappropriate Like XLH
Autosomal recessive
hypophosphatemic rickets
Normal/high Low Low Low or inappropriate Like XLH
Tumor-induced osteomalacia Variable: normal/
low/high
Low Low Low ‐ Surgery (resection of tumor)
‐ Phosphate supplementation
and calcitriol or alfacalcidiol
Hypophosphatemia due to
renal transplantation
Normal/high Low Low Normal/low Phosphate supplementation
and calcitriol or alfacalcidiol
McCune-Albright Normal/high Normal/low Normal/low Normal/low Phosphate supplementation
and calcitriol or alfacalcidiol
Disorders that are non-FGF-23-
mediated
Hereditary hypophosphatemic
rickets with hypercalciuria
Variable: normal/
low
Low Low High Phosphate supplementation
Fanconi syndrome Normal/high Normal/low Normal/low Normal/low Phosphate supplementation
and calcitriol or alfacalcidiol
References: [1, 32, 41, 49]
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does not appear to be influenced in either a positive or nega-
tive way by standard treatment of XLH.
Dental abscesses of deciduous and permanent teeth are a
common clinical complication in these patients and, often,
after repeated infection, permanent teeth are lost in young-
adulthood. Moreover, root dysplasia and enlarged pulp cham-
bers can be identified by radiographic examinations. There are
structural abnormalities that increase the risk of dental ab-
scesses, such as poorly mineralized and thinner dentin and
cementum layers, and possibly enamel abnormalities [48].
Regarding the pathogenesis, FGF-23 is expressed in odonto-
blasts, and hypophosphatemia may contribute to the dental
pathology [48].
Adult XLH patients, as well as in other hypophosphatemic
rickets, can present with variable hearing loss [49]. These
subjects may have mild-to-severe sensorineural hearing loss
(affecting especially low and high frequencies). X-ray exams
show generalized osteosclerosis and thickening of the petrous
bone, with narrowed internal auditory meatus. In some cases,
tinnitus and vertigo can be associated with low frequency
hearing loss [49].
Biochemical expression
XLH is typically characterized by hypophosphatemia, renal
phosphate wasting, reduced tubular maximal reabsorption of
phosphate adjusted for glomerular filtration rate (TmP/GFR),
and inappropriately low or normal 1,25(OH)2D3 serum con-
centrations, while serum 25-vitamin D [25-(OH)D] is usually
normal. Serum alkaline phosphatase (ALP) activity is elevat-
ed, principally from a bone source, and it represents an impor-
tant parameter for disease control, as well as efficacy of ther-
apy [4]. Generally, patients affected by XLH have normal
serum calcium levels; however, secondary hyperparathyroid-
ism is common in this disease, both without treatment with
phosphate and as a potential consequence of phosphate treat-
ment. Additional laboratory findings that could lead to diag-
nosis include high plasma levels of FGF-23, although a nor-
mal level of FGF-23 of medium-high range would be consid-
ered inappropriate for this degree of hypophosphatemia and
would also be consistent with a diagnosis of XLH [4]. It is
important to consider other differential diagnoses, as discussed
below, leading to hypophosphatemic hyperphosphaturic rick-
ets, especially when a familial history is present [4].
Other diseases with features
of hypophosphatemia due to renal phosphate
wasting
In addition to XLH, other diseases with features of
hypophosphatemia due to impaired proximal tubular reab-
sorption of phosphate, mediated by FGF-23 excess, include
autosomal-dominant hypophosphatemic rickets (ADHR), au-
tosomal recessive hypophosphatemic rickets (ARHR), tumor-
induced osteomalacia (TIO), and hypophosphatemia associat-
ed with fibrous dysplasia of bone/McCune-Albright syn-
drome (see Table 1) [1].
Several other rare disorders may variably manifest as
FGF23-associated hypophosphatemia as a clinical feature;
such disorders include epidermal nevus syndrome, neurofi-
bromatosis, osteoglophonic dysplasia, hypophosphatemic
rickets with hyperparathyroidism, and hypophosphatemia as-
sociated with parenteral iron therapy [11, 50, 51]. In contrast,
hereditary hypophosphatemic rickets with hypercalciuria
(HHRH), and Fanconi syndrome are FGF23-independent
forms of renal phosphate wasting (see Table 1).
Autosomal-dominant hypophosphatemic rickets
Definition
ADHR is a rare disease with clinical and biochemical findings
similar to XLH [52].
Cause
ADHR is caused by a missense mutation in FGF-23 gene
itself, leading to alteration in the RXXR furin protease recog-
nition site, that renders FGF-23 resistant to proteolytic cleav-
age [32]. Mutant FGF-23 proteins have increased stability, are
more active than wild-type FGF-23, in vivo, and in these
patients are likely present at high levels [53]. Therefore, ele-
vated circulating concentrations of FGF-23 are caused by its
reduced degradation.
Clinical expression
The expression of the disease can vary, and in some cases,
despite carrying the gene mutation, hypophosphatemia never
develops [44, 54]. Patients, manifesting the disease in child-
hood, usually develop short stature, rickets, lower extremity
deformities, bone pain, and dental abscesses. However, in
some cases, the children show spontaneous resolution of
symptoms during adulthood. In adulthood, patients can have
symptoms similar to patients with TIO, developing
hypophosphatemic osteomalacia, and clinical manifestations
can include also bone pain, weakness, and fractures/
pseudofractures [54]. Moreover, it has been described that
most patients who develop the disease in adulthood are wom-
en, and pregnancy appears to be a trigger of the onset of symp-
toms [54]. Some affected females have demonstrated delayed
expression of the disease features; in contrast, some individ-
uals have lost the renal phosphate wasting defect after puberty.
Currently, it is not clear why patients only sometimes generate
inappropriate FGF-23 and hypophosphatemia. However,
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some studies suggested that, both in ADHR patients and in a
mouse model of ADHR, iron status may regulate FGF-23
metabolic pathways and that low iron status results in in-
creased FGF-23 mRNA [54, 55]. As the risk for iron deficien-
cymay increase at the time of puberty, a potential for increased
expression of FGF-23 during this time exists and may lead to
the development of a subclinical disorder [55].
Biochemical expression
In patients with active disease, the biochemical profile is char-
acterized by hypophosphatemia, phosphaturia, and inappro-
priately normal or low 1,25(OH)2D3 concentrations, as in
XLH [54]. Some patients alternate between periods of
hypophosphatemia and normophosphatemia, coinciding with
differences in FGF-23 concentrations [55, 56].
Autosomal recessive hypophosphatemic
rickets
Definition
ARHR is another rare hereditary renal phosphate wasting dis-
order characterized by hypophosphatemia, rickets, and/or os-
teomalacia and slow growth [32, 52].
Cause
ARHR type 1 is due to a mutation in the gene encoding the
protein DMP1, a member of the small integrin-binding ligand
N-linked glycoprotein family of extracellular matrix proteins
that augment mineralization. Loss of function of DMP-1
causes an increased transcription of FGF-23 by osteocytes;
however, the mechanism is not fully clear [31, 44]. Of note,
DMP-1 is widely expressed but particularly abundant in bone,
where it is synthesized by osteoblasts, and it is involved in the
regulation of transcription in undifferentiated osteoblasts.
Moreover, another form of ARHR was identified as ARHR
type 2 caused by an inactivating mutation in the ENPP1 gene.
The gene product ectonucleotide pyrophosphatase/
phosphodiesterase 1 is a cell surface enzyme responsible for
generating inorganic pyrophosphate that is able to inhibit
bone. Loss-of-function mutations in ENPP1 can cause gener-
alized arterial calcification of infancy mineralization [57].
Clinical expression and biochemical expression
Clinical and biochemical features are similar to ADHR and
XLH, with the exception of a relatively higher bone mineral
density (BMD) [32]. Indeed, clinical manifestations include
rickets, skeletal deformities, dental defects, sclerotic bone le-
sions, and enthesopathies. Affected subjects show signs of
rickets/osteomalacia later during childhood and even in adult-
hood [32]. In these patients, FGF-23 concentrations are high,
but the exact mechanism has yet to be understood.
Hereditary hypophosphatemic rickets
with hypercalciuria
HHRH is a hereditary hypophosphatemic disorder resulting
from specific transporter mutations [58]. It is a rare autosomal
recessive disorder, due to a mutation in the SLC34A3 gene,
which encodes the NPT2c renal phosphate cotransporter,
resulting in primary renal phosphate loss [58].
This disease is characterized by hypophosphatemia, rickets,
osteopenia/osteomalacia, and renal phosphate wasting, and, in
contrast to XLH, urinary calcium excretion can be consider-
ably elevated, and circulating PTH is usually low to low-nor-
mal. In this condition, FGF-23 is appropriately downregulated
and the hypophosphatemia causes the expected increase in
1,25(OH)2D3 levels [59]. This finding differs from the
FGF23-mediated decrease in expression of CYP27B1
(encoding 1a-hydroxylase) and thus low or normal levels of
1,25(OH)2D3 observed in XLH, ADHR, and ARHR. Both the
human disorder of HHRH due to NPT2c mutations and the
mouse models of npt2c or npt2a deficiency show that in-
creased 1,25(OH)2D3 levels result in increased calcium absorp-
tion and consequent hypercalciuria [58]. In addition to phos-
phate wasting and rickets, renal stones may occur, and the
hypercalciuria is likely to play a role in stone formation [60].
Fibrous dysplasia and McCune-Albright
syndrome
Fibrous dysplasia (FD) is a genetic, non-inherited disorder
caused by somatic activating missense mutations of the sig-
naling protein GS alpha (GNAS1 gene), encoding the α
subunit of the stimulatory G protein, Gs. This is a non-
neoplastic disease affecting the skeleton as monostotic or
polyostotic forms or in variable combinations with endocrine
and cutaneous abnormalities in case of McCune-Albright
syndrome (MAS). Hypophosphatemic rickets/osteomalacia
is a rare clinical complication of FD/MAS. In approximately
50% of FD/MAS patients, renal phosphate wasting is report-
ed [61]. Indeed, some patients develop hypophosphatemia,
high FGF-23 levels, and a decreased TmP/GFR, though the
mechanisms responsible for FGF-23 overproduction by FD
tissue are unknown [62, 63]. Hypophosphatemia is a key
predictor of future fragility fracture risk for people with
FD/MAS [62]. 99Tc scintigraphy is useful when bone FD
is suspected [4].
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Tumor-induced osteomalacia
Definition
TIO is a rare paraneoplastic syndrome characterized by
hypophosphatemia due to renal phosphate wasting in adult
subjects and osteomalacia. This disease may be associated
with mesenchymal tumors. Hypophosphatemia is caused by
unregulated oversecretion of FGF-23, derived usually by
small and mesenchymal tumors. The incidence and preva-
lence are not known; in literature, more than 300 cases of
TIO have been reported [38].
Cause
The diagnosis is commonly delayed for years, due to
underrecognition of the disease. The most common tumor
associated to TIO is hemangiopericytoma, followed by other
tumors, such as hemangioma, sarcomas, myxoma, ossifying
fibromas, granulomas, giant cell tumors, neurofibromatosis,
schwannoma, and prostatic tumor and osteoblastomas [64].
Most of the tumors are slow growing, benign, and extremely
vascular mesenchymal tumors involving soft tissue and bone.
The prototypical phosphaturic mesenchymal tumor (mixed
connective tissue variant) contains neoplastic cells that are
spindled to stellate in shape, normochromatic with small nu-
clei and indistinct nucleoli. A prominent feature of these tu-
mors is an intrinsic microvasculature with an admixture of
vessel size and vascular pattern [64]. These tumors can occur
from head to toe, and unusual locations have included the
nasopharynx, the maxilla, and the palm of the hand.
Occasional malignant tumors have been reported [1, 38].
TIO tumors can be subdivided into four different types:
mixed connective tissue variant (phosphaturic mesenchymal
tumor mixed connective tissue variant), osteoblastoma-like
variant, non-ossifying fibroma-like variant, and ossifying
fibroma-like variant. The first group is diagnosed in 70–80%
of TIO cases and comprises neoplasias containing primitive
stromal cells, prominent vessel, and osteoclast-like giant cells.
These tumors usually occur in bones or soft tissues and are
typically benign in behavior, except some cases of malignant
variants with sarcomatous features [65]. The other three
groups tend to occur in bones and are also usually benign. In
about 70% of the cases studied, FGF-23 is positive, and the
proliferating cells within the tumor are usually the source of
FGF-23 [64]. In several cases of TIO tumors, somatostatin
receptors were described [66].
Clinical expression
Clinical manifestations are generally non-specific and often
progressive, including muscle and bone pain, which is usually
the first presentation, prominent proximal muscle weakness,
osteomalacia/rickets, sometimes height and weight loss, and
high risk of fractures (especially in the ribs, vertebral bodies,
and femoral neck) [38]. Clinically, it most commonly occurs
in young-adult subjects. The diagnosis is usually delayed for
years (about 5), due to the non-specific nature of the present-
ing symptoms, failure to evaluate hypophosphatemia, and dif-
ficulty in localizing the responsible tumor [38]. The clinical
suspicion of TIO should be set for any patient with osteoma-
lacia for which there is not obvious cause or familial history.
Biochemical expression
Laboratory exams should evaluate renal phosphate wasting
with decreased Tmp/GFR, fasting hypophosphatemia, inap-
propriate (normal or low) 1,25(OH)2D3 concentrations, nor-
mal serum calcium, PTH, and 25- hydroxyvitamin D
[25(OH)D] levels. Numerous reports show elevation of FGF-
23 in some but not all patients with TIO. In some cases, PTH
can be high, reflecting secondary hyperparathyroidism, which
may be in part due to low 1,25(OH)2D3 caused by elevated
FGF-23 levels. In 5% of patients with TIO, tertiary hyperpara-
thyroidism can occur [67]. Moreover, levels of ALP are usu-
ally elevated because of osteoblastic hyperactivity and active
bone remodeling in the context of active osteomalacia [38].
Diagnosis
The diagnosis of TIO can be challenging because the tumors
are often small and difficult to find. It is important to scan the
whole body, including extremities, which is often excluded in
routine nuclear medicine imaging, as tumors can occur any-
where in the body. It is difficult to identify the tumor associ-
ated with TIO, and several instrumental exams have been
employed in an effort to localize the tumor. Octreotide scan-
ning is commonly performed with 111 In-labeled
pentatreotide. Octreotide scintigraphy is successfully used to
locate tumors in up to 95% of patients with TIO [38].
Fluorodeoxyglucose (18FFDG) PET/CT and gallium (68Ga)
DOTATATE PET/CT have also been used successfully in
identifying candidate tumors. Other localizing studies that
have been used include total body magnetic resonance imag-
ing, computed tomography, and selective venous sampling for
FGF-23 [38]. Finally, single-photon emission tomography
(SPECT) or hybrid SPECT/CT enables three-dimensional im-
aging and better tumor contrast but usually is limited to areas
of suspected abnormality rather than a whole body survey
[38]. Total body magnetic resonance imaging and computed
tomography should be used to confirm the site of the tumor
after identification by functional imaging [38]. In some cases,
the tumor is occult and difficult to locate, or the tumor may
take several years to manifest clinically. In case of tumor lo-
cation failure, imaging exams should be repeated every 1–
2 years [38].
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TIO should be included in the differential diagnosis in pa-
tients with progressive weakness, bone and muscle pain, and
multiple fractures. However, in many cases, TIO is
misdiagnosed with other musculoskeletal, rheumatologic dis-
eases, or even psychiatric diseases. Differential diagnosis
should also include renal Fanconi’s syndrome, a disease of the
proximal renal tubules, characterized by impaired phosphate
reabsorption and low levels of phosphatemia and additionally
amino aciduria, glycosuria, and low serum bicarbonate that are
not present in FGF-23-mediated hypophosphatemia [38].
Removal of the responsible tumor leads to reversal of typ-
ical TIO features, and the diagnosis is confirmed by the dra-
matic improvement of symptoms and correction of metabolic
abnormalities following its complete excision. Measurement
of serum levels of FGF-23 should be performed to confirm the
diagnosis. Confirmation of disease causing mutation within
phosphatonin genes may also be performed. Bone
histomorphometric analysis can confirm the excess osteoid
of bone tissue [38].
Differential diagnosis of renal phosphate
wasting disorders
In case of suspicion of renal phosphate wasting diseases, the
first step must be to determine whether urinary phosphate
excretion is appropriate, followed by careful medical history
and objective examination to help distinguish the various
forms.
Indices of phosphate excretion, such as tubular maximal
reabsorption of phosphate, adjusted for glomerular filtration
rate (TmP/GFR), allow us to determine if renal loss is or is not
a factor in causing hypophosphatemic state. Paired morning
fasting serum and 2-h urinary creatinine and phosphate levels
while the patient is off phosphate therapy for at least 24 h are
required. The tubular reabsorption of phoshate (TRP) can be
used to calculate TmP/GFR: TRP = 1 − (fractional excretion
of phosphate) = 1 − ([Urine phosphate] / [plasma phosphate] ×
[plasma creatinine] / [urine creatinine]). In case of TRP ≤
0.86, phosphate reabsorption is maximal and there is a linear
relationship between plasma phosphate concentration and ex-
cretion, and TmP/GFR is calculated as follows: TmP/GFR =
TRP × [plasma phosphate]. In case of TRP > 0.86, TmP/GFR
is defined as follows: TmP/GFR = 0:3 × TRP / {1 − (0:8 ×
TRP)} × [plasma phosphate] [1]. Another method to measure
TmP/GFR is the use of a nomogram after measuring fasting
plasma and urine phosphate and creatinine concentrations
[68]. Like serum phosphate, TmP/GFR is higher in young
children than adults [1].
Regarding biochemical expression of the genetic phos-
phate wasting disorders and TIO, Table 1, as already de-
scribed, summarizes the typical laboratory test alterations.
A low serum 1,25(OH)2D3 concentration in a patient with-
out advanced CKD (stages 4 to 5) and with an adequate
25(OH)D level signal the possibility of a hypophosphatemia
due to excess FGF-23 levels. The measurement of FGF-23
may be helpful, but this test is not available widely, as already
described. It is important to remember that sample type, rapid
sample centrifugation and freezing, and choice of assay are
factors that affect FGF-23 levels. Moreover, in patients with
XLH, plasma FGF-23 concentrations are elevated but are
quite variable [69]. During hypophosphatemia, iFGF-23 con-
centration greater than the normal population mean, which
according to the assays used is approximately 30 pg/ml,
should be considered inappropriately elevated and likely caus-
ative of the hypophosphatemia [69, 70]. However, an elevated
FGF-23 concentration is not specific for XLH, even in the
setting of hypophosphatemia, since ADHR, ARHR, TIO,
and FD cause FGF-23-mediated hypophosphatemia.
Nevertheless, a low FGF-23 concentration in the setting of
hypophosphatemia suggests a different cause, such as
Fanconi syndrome, dietary phosphate deficiency, or malab-
sorption [69, 70].
Lastly, an accurate pathological and pharmacological med-
ical history allows to exclude other acquired causes of renal
wasting disorders in the differential diagnosis.
Treatments for phosphate wasting disorders
Therapy for XLH
Current standard of care and monitoring
Current standard treatment of phosphate wasting genetic dis-
orders is based on treatment of the XLH, due to similarities in
pathophysiology between the pathologies. However, most of
the published studies treating XLH are uncontrolled or use
only historical controls, and there is a lack of specific studies
on the less common diseases [62]. The most commonly pre-
scribed medical therapy consists of calcitriol or 1 alfacalcidol
and phosphate supplementation, especially for children, from
the time of diagnosis until growth is complete. Subsequently,
in adulthood, the need for treatment must be carefully evalu-
ated, balancing potential benefits with known risks such as
nephrocalcinosis and hyperparathyroidism, and the treatment
requires ongoing monitoring. Currently, there is no consensus
regarding indications of the treatment in adult subjects affected
byXLH and overall by hypophosphatemic rickets.Many adult
patients do not have clinical manifestations without treatment,
while others can develop bone pain and pseudofractures [62].
It is mostly accepted that treatment should bemaintained or
reinitiated in all patients in case of pain, which may be caused
by bone microfractures and/or osteomalacia [41, 49]. In case
of planed surgical interventions, such as corrective osteotomy,
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or dental implants, the patients should be treated at least for a
period to promote bone mineralization [41, 49]. Moreover,
adult patients could be treated with pharmacological approach
in case of spontaneous insufficiency fractures, which may heal
faster with therapy. In case of orthopedic procedures, the treat-
ment could reduce recovery time and the risk of prosthetic
loosening in patients undergoing joint replacement, with high
serum ALP activity, osteomalacia, and bone pain [41].
Enthesopathy, in adult patients, does not seem to improve with
current medical therapy, and risk factors associated with its
occurrence are unknown [41, 47]. In case of pain and joint
stiffness, appropriate rehabilitation should be associated to
pharmacological management [49].
In asymptomatic adult patients, the treatment with phos-
phate and vitamin D analogs is debatable, due to the absence
of clear evidence for positive clinical benefits and the possible
side effects. On the other hand, long-term consequences of
chronic low serum phosphate levels in adult subjects are not
known [49]. A chronic reduced 1,25(OH)2D3 synthesis may
have an important clinical role, considering its beneficial ef-
fects onmetabolism, cardiovascular and immune systems, and
tumor prevention [49].
In case of increased demands on phosphate and calcium,
such as pregnancy, the pharmacological treatment could be
administered, in order to ensure sufficient mineralization of
the fetal skeleton, or in case of lactation, in order to allow an
adequate galactopoiesis, and prevent worsening of the phos-
phate deficit in the mother in both these physiological situa-
tions. However, so far, there are not studies that prove it [49].
The current goal of treatment of XLH in adult patients is
not necessarily and specifically to normalize the serum phos-
phate levels but rather to improve the symptoms, osteomala-
cia, accelerate fracture healing, and decrease the number of
necessary surgeries. Although the treatment reduces symp-
toms, hyperphosphaturia persists, since the treatment does
not alter the impaired tubular phosphate reabsorption [41, 49].
The conventional treatment in adult patients is based on
oral phosphate salts, usually given two to four times/day,
and active vitamin D metabolites. Most XLH treatment stud-
ies do not consistently report weight-based dosing of calcitriol
and phosphate, and the reported doses vary widely (phosphate
supplements = 0–2000mg/day, two to four times/day; vitamin
D analogs, alfacalcidol = 0–1.5 mcg/day, equivalent dose in
calcitriol was obtained divided by a factor 2, once or twice/
day) [32, 41, 49]. Frequent dosing is useful to avoid a rapid
decline of the available drug and to reduce volatility in serum
phosphate levels. Moreover, the use of liquid formulations
may improve adherence to therapy and allow more precise
dosing.
Treatment with these two agents should be carefully mon-
itored to guarantee an adequate balance. Gradual titration up
to target doses of oral phosphate salts is advised, since high
doses can cause gastrointestinal side effects, such as
abdominal pain or diarrhea. Small doses are usually pre-
scribed and subsequently titrated toward targets to minimize
gastrointestinal symptoms. Some patients may need smaller
doses based on their weight, whereas others may require doses
mildly above these ranges [41].
The use of monotherapy with only phosphate salts is not
appropriate and is ineffective. Oral phosphate monotherapy
does not adequately improve osteomalacia, and it is associated
with a relevant risk of iatrogenic hyperparathyroidism.
Phosphate supplementation alone increases serum phosphate,
decreases ionized calcium, and consequently increases PTH
levels. On the other hand, the association of active analogs of
vitamin D and oral phosphate significantly improves the oste-
omalacia, and activated vitamin D has a suppressive effect on
PTH, given that it increases gastrointestinal calcium and phos-
phate absorption [71].
The major risks of long-term therapy with calcitriol and
phosphorus in adult subjects with XLH are similar to those
in children, such as hypercalcemia and hypercalciuria [41].
Special attention should be given to potentially severe side
effects such as nephrocalcinosis, leading in some cases to
CKD. This renal complication is probably due to the high
throughput of calcium and phosphate induced by pharmaco-
logical treatment, causing hypercalciuria, and simultaneously
continuous renal losses. Moreover, treatment with phosphate
can cause secondary and tertiary hyperparathyroidism.
Despite the described benefits of this pharmacological treat-
ment, it tends to increase FGF-23 in both the Hyp mouse and
humans with XLH [62, 73], but the clinical consequences of
this rise in FGF-23 are uncertain. A cross-sectional analysis of
a small number of treated patients showed that FGF-23 con-
centrations did not correlate with indices of disease severity
[70]. However, high FGF-23 levels may have deleterious ef-
fects on the health of these subjects, of note on metabolism
and cardiac functions [49].
Careful laboratory monitoring is essential to minimize the
risks associated to pharmacological treatment. Laboratory
monitoring, including serum calcium, phosphorus, creatinine,
bone alkaline phosphatases and PTH, and 24-h urinary excre-
tion of calcium or a fasting spot urinary calcium/ creatinine
ratio, is recommended every 3–4 months during the first year
of treatment, or if there are dosing changes or changes in the
patient calcium intake through diet and/or supplementation, in
order to avoid complications, such as hypercalcemia, hyper-
calciuria, or hyperparathyroidism [41, 49]. After the first year,
treated adult patients should be monitored every 6–12months.
In case of hypercalcemia or hypercalciuria, the calcitriol dose
must be reduced [41]. Serum ALP activity is the most useful
biomarker for drug effects on bone response, serving as a
surrogate marker for bone healing. During the first few
months of therapy, serum ALP activity may transiently rise
and during the initial healing phase of the osteomalacia. To
prevent secondary hyperparathyroidism, PTH levels are
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commonly measured, and in case of increasing PTH levels,
the calcitriol dose can be increased, or the phosphate dose can
be reduced. The optimal amounts of these two drugs are de-
termined by monitoring serum and urine calcium [41].
Renal ultrasonography can be performed at 2- to 5-year
intervals to detect moderate to severe, or progressive,
nephrocalcinosis. Radiography and computed tomography are
not recommended for monitoring, and unnecessary radiation
exposure should be avoided [41]. Moreover, technetium bone
scans may be useful in case of suspected stress fractures [41].
Finally, clinical monitoring should provide an annual as-
sessment of weight control, mobility, pain, and any dental
problems. In case of pregnancy, the clinical monitoring will
be every 3 months [49].
GH treatment
Treatment with recombinant human growth hormone (GH)
was shown to improve growth velocity and thus standardized
height without aggravating preexisting body disproportion in
short children with XLH despite regular treatment with active
vitamin D and phosphate [73–76]. However, it remains to be
proven if this treatment is able to increase adult height in short
children with XLH, since adequately powered studies on this
topic are lacking [77]. Therefore, outweighing the potential
benefits, costs, and side effects, it is not recommended as a
routine treatment for this disease [32, 75].
Treatments of dental and hearing complications
Dental complications, especially root abscess, are an important
problem in adult patients with XLH. Defective dentin and
microdefects in the enamel increase microorganism access to
the pulp chamber, resulting in abscess formation. These pa-
tients are subjected to numerous root canals and tooth extrac-
tions [62]. Therefore, consistent dental hygiene, including
brushing two to three times a day and regular dental hygienist
visits, is recommended. No specific therapy has been clearly
demonstrated to prevent this complication. The role of sealant
application on the incidence of root abscesses is currently be-
ing studied [41, 62]. Future investigations will have to deter-
mine the possible benefit of treatment with vitamin D analogs
and phosphate supplements on the periodontal status [49].
Regarding hearing impairments in patients with XLH, cur-
rently, it is not known whether phosphate supplements and
vitamin D analogs can modify the hearing evolution [49].
Surgical treatments
Surgical approach is usually indicated for the treatment of
severe bowing, tibial torsion, or pathological fractures unlikely
to improve with medical management. Prophylactic surgery is
indicated to reduce future fracture risk and/or improve lower
limb alignment. Osteotomywith plating,multiple osteotomies,
and intramedullary fixation are standard methods for surgical
management [78].
It has been described that the healing time after orthopedic
surgery in untreated patients varies between 6 months and
1 year, whereas pharmacological treatment can shorten it
[41]. Moreover, it has been described that the treatment ap-
pears to reduce the risk of prosthetic joint loosening, so it is
recommended to begin therapy in untreated patients 3–
6 months before the operation and continue for 6–9 months
afterwards [41].
Future treatments for XLH
After the identification of FGF-23 as a humoral mediator of
phosphate wasting in XLH disease, and further discoveries
regarding its pathophysiology, much effort has been directed
toward newer pharmacological strategies that target the FGF-
23 pathway. In addition to this, several novel treatments are
being studied, including methods to modulate PTH levels,
modulate the downstream consequences of high FGF-23 con-
centrations, alter FGF-23 production or degradation, and
block the negative effects of FGF-23. In the future, another
interesting pharmacological target could directly modulate the
activity of the renal sodium-phosphate cotransporters, on
which FGF-23 acts [62].
Calcimimetics and thiazide diuretics or amiloride
in XLH
Cinacalcet is a calcimimetic that has recently been approved
for the treatment of secondary hyperparathyroidism in end-
stage renal disease and for the treatment of primary hyperpara-
thyroidism due to parathyroid adenoma, carcinoma, or hyper-
plasia, not operable surgically. It is an allosteric modulator of
the calcium-sensing receptor (CaR), with a suppressive effect
on PTH secretion, the tubular reabsorption of calcium, and the
serum calcium concentration in patients with hyperparathy-
roidism. In addition, it may indirectly reduce FGF-23 concen-
trations [79].
During the standard treatment with calcitriol and phosphate
supplementation for several years in for XLH patients,
cinacalcet could be used to normalize PTH values in case of
significant and persistent secondary or tertiary hyperparathy-
roidism, especially if accompanied by rising serum ALP
levels. Initial doses of 30 mg at bedtime can be increased to
60 mg, but the data regarding the therapeutic response de-
scribed in the literature are scarce and variable [41, 80]. A
study conducted on eight patients with the diagnosis of XLH
showed that single doses of cinacalcet plus an oral phosphate
dose increased serum phosphate and TmP/GFR compared to
phosphate alone in XLH, while suppressing PTH compared to
phosphate plus calcitriol [81]. Moreover, a case report
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described that the addition of cinacalcet reduced PTH and
calcium levels and increased serum phosphate, as was expect-
ed, but also reduced FGF-23 levels, which remained stable
after 6 months of therapy [82]. However, in a recent study in
Hyp mice an orthogous animal model of XLH, monotherapy
with cinacalcet (R568) reduced PTH and FGF-23 synthesis in
bone but failed to restore vitamin D and phosphate metabo-
lism and skeletal abnormalities [83]. Therefore, long-term
clinical trials should be conducted in order to investigate
cinacalcet’s potential as an adjuvant treatment of XLH [62].
Calcitonin
Calcitonin also stimulates 1,25(OH)2D3 production in patients
with XLH, and its administration was shown to lower FGF-23
concentrations for several hours after a single dose [85].
Moreover, there was an increase in serum phosphorus and
1,25(OH)2D3 following calcitonin administration, without a
significant change in the TmP/GFR [84]. Since osteocytes are
the primary source of FGF-23, these findings imply that the
decline in FGF-23 levels observed in patients with XLH was
likely due to the direct effect of calcitonin on osteocytes [84].
However, the use of calcitonin is much debated. In 2012,
the European Medicines Agency (EMA) carried out a review
regarding the benefits/risks associated to the use of calcitonin,
concluding that there was evidence of a small increased risk of
cancer with its long-term use. The Agency’s Committee for
Medicinal Products for Human Use recommended that
calcitonin-containing medicines should only be authorized
for short-term use in Paget’s disease, acute bone loss caused
by immobilization, and hypercalcemia due to cancer.
Moreover, the committee concluded that the benefits of calci-
tonin did not outweigh their risks for the osteoporosis therapy
and, therefore, that they should no longer be used for this
disease. After a reexamination, the committee confirmed its
recommendation also in 2012 [85]. On the other hand, there
are some calcitonin salmon products approved by the Food
and Drug Association (FDA) to treat postmenopausal osteo-
porosis, since, so far, the FDA’s review of these products
found there is no conclusive evidence of a causal relationship
between the use of these products and cancer risk. The FDA
will continue to reevaluate this issue as more information be-
comes available, and currently, these products represent an
option for those patients who cannot or do not want to use
other treatments for osteoporosis. The FDA recommends that
healthcare professionals continue to assess each patient’s ben-
efits and risks of all available treatments [86].
Hexa-D-arginine
Another pharmacological approach for the inhibition of the
FGF-23 pathway could be a C-terminal fragment of FGF-23,
which in studies conducted in Hyp mice has been shown to
successfully increase serum phosphate and 1,25(OH)2D3
levels [62].
Hexa-D-arginine (D6R) is a small peptide that stimulates
7B2 mRNA expression, enhances 7B2-SPC2 activity, and de-
creases FGF-23 mRNA [62]. So far, preliminary data have
shown that hexa-arginine upregulates the subtilisin convertase
system, degrading FGF-23 [62]. It suggests that this agent
could be used to reduce circulating intact FGF-23 levels in
patients with XLH [62].
FGF23 neutralizing antibodies
With recent discoveries, much effort has been directed toward
new strategies that specifically target the FGF-23 pathway.
Indeed, recent studies have been conducted and focused on
the use of anti-FGF-23 antibodies (KRN23) as a possible
treatment for patients with XLH.
KRN23 is a recombinant fully human IgG1 monoclonal
antibody, developed to treat XLH by binding to FGF-23 and
inhibiting its activity, to restore a normal phosphate homeo-
stasis [87]. KRN23 is expressed in Chinese hamster ovary
dihydrofolate reductase-deficient cells. This new agent binds
the amino-terminal domain of FGF-23 that interacts with the
FGF-binding portion of the combination FGFR1/Klotho re-
ceptor, preventing FGF-23 from binding to and signaling from
its receptor. Both intact and fragmented FGF-23 polypeptides
are immunoprecipitated with KRN23. Therefore, KRN23 re-
stores tubular reabsorption of phosphate (TmP/GFR) from the
kidney and increases the production of 1,25(OH)2D3. This
dual action should improve serum phosphorus concentration,
which is expected to improve bone mineralization and reduce
the diverse bone and non-bone manifestations in XLH [87].
Regarding non-clinical studies in the Hyp mouse, the use
of KRN23 resulted in inhibition of endogenous FGF-23 activ-
ity and in increase of circulating phosphate and 1,25(OH)2D3
levels [87]. In short- and long-term treatment studies, a reduc-
tion of phosphaturia and improvement of phosphatemia and
1,25(OH)2D3 levels have been observed [88]. After 4 weeks
of treatment, decreased unmineralized osteoid thickness, im-
proved growth, decreased growth plate thickness, and partial
correction of the osteomalacia were reported. In addition, the
length and shape of the Hyp mouse femur improved during
treatment with FGF-23 neutralizing antibodies [88]. These
antibodies also improved muscle weakness as demonstrated
by the improvement of spontaneous motor activity and grip
strength in Hyp mice [88].
A similar antibody to human FGF-23 is currently under
investigation in clinical trials as a potential therapeutic agent
for XLH in humans [89–91]. In adult patients with XLH, three
clinical studies have been conducted, including a single dose
phase 1 safety and tolerability study of KRN23 (KRN23-US-
02), a repeat-dose phase 1/2 dose escalation study (KRN23-
INT-002), and an associated treatment extension study
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(KRN23-INT-002). A phase 2 dose-finding, pharmacodynam-
ic, and safety study is also being conducted in pediatric XLH
patients (UX023-CL201).
In the phase 1 study, KRN23 increased TmP/GFR, serum
phosphorous, and 1,25(OH)2D3 levels, and patients had no
increased risk of nephrocalcinosis, hypercalciuria, hypercalce-
mia, anti-KRN23 antibodies, or elevated serum PTH or creat-
inine levels. The half-life of KRN23 after subcutaneous dos-
ing was 13–19 days, and serum phosphorus remained higher
than baseline beyond 4 weeks, supporting dosing every
4 weeks [92, 93].
Subsequently, a multicenter phase 1/2 open-label, dose es-
calation study was conducted to evaluate the safety and effi-
cacy of subcutaneous KRN23 administered every 28 days for
four doses, followed by a 12-month extension study, in order
to test the hypothesis that monthly KRN23 would safely im-
prove serum phosphorus in adult patients affected by XLH
[96]. Repeated doses of KRN23, up to 1.0 mg/kg, were well
tolerated by adult subjects throughout the phase 1/2 dose es-
calation and associated treatment extension study. In all pa-
tients, monthly KRN23 significantly increased serum phos-
phorus, TmP/GFR, and 1,25(OH)2D3 levels [94].
Throughout the study, adverse events were reported in 27 of
the 28 subjects and 18 subjects (64%) had adverse events
considered drug-related, such as diarrhea and arthralgia and
injection site reactions. Six grade 3 adverse events occurred,
once each among five subjects (myalgia, extremity pain, cer-
vical spine stenosis, breast cancer, hypertensive crisis, all un-
related to study drug, and restless leg syndrome, related to
study drug). No deaths were described. Overall, anti-KRN23
antibodies were not detected in any subject, and no patterns of
dose-limiting toxicity have been associated with KRN23 treat-
ment [94].
Therefore, single and repeat-dose clinical studies show that
subcutaneous administration of KRN23 consistently in-
creased and sustained serum phosphorus levels and TmP/
GFR, without major alterations of vitamin D metabolism or
urine calcium levels. The data derived from the long-term
extension study shows that KRN23 could provide sustained
increases in serum phosphorus levels and improve bone phys-
iology, structure, and function [94]. Currently, a randomized,
double-blind, placebo-controlled, phase 3 study to assess the
efficacy and safety of KRN23 in adults with XLH is ongoing
(UX023-CL303).
Finally, a recent study (phase 1/2, open-label, multicenter,
dose escalation trial) has been conducted to validate the use of
SF-36v2 Health Survey (SF-36v2) and the Western Ontario
and McMaster Osteoarthritis Index (WOMAC) in order to
measure the health-related quality of life (HRQoL) in 28 adult
patients with XLH and determine the change in HRQoL be-
fore and after treatment with KRN23. The drug was adminis-
tered subcutaneously up to four doses every 28 days. The use
of KRN23 was associated with significantly improved patient
perception of their physical functioning and stiffness related to
their disease. This investigation showed that the SF-36v2 and
WOMAC could be valid tools for assessing HRQoL in these
patients and in the future could provide a valuable addition to
other criteria in evaluating new treatment options in adult
subjects affected by XLH [95].
Current standard of care of TIO
The gold standard treatment for TIO is the surgical resection
of tumor with a wide margin, to avoid recurrences [96]. After
tumor removal, within days to weeks, FGF-23 disappears rap-
idly from the blood circulation, renal phosphate wasting de-
creases, 1,25(OH)2D3 concentration increases, and serum
phosphate levels return to normal by day 5 after operation
[38, 97]. Bone healing starts immediately, but, depending on
the severity of the disease, it may take a short time or more
than a year for a significant clinical improvement. Most pa-
tients feel better within days to weeks of tumor removal [38].
In case of incompletely resected tumors, post-operative ra-
diotherapy for margin positive tumors used to avoid recur-
rence or metastasis has been described, but data are still lim-
ited [67, 96]. Subsequent radiotherapy can be used to avoid
recurrence or, rarely, metastases, in less than 5% of the pa-
tients with TIO [64, 67]. The course after metastasis is quite
variable, and survival of up to 30 years has been reported [98].
So far, there is no chemotherapywith demonstrated efficacy in
treating metastatic TIO.
In case the tumor is not localizable or is not surgically
resectable, medical treatment with phosphate supplementation
and calcitriol or alfacalcidiol is usually used, as in XLH (see
previous section).
Image-guided ablation with radiofrequency or cryoablation
is a promising alternative for these patients [99]. Although
surgery remains the treatment of choice, image-guided abla-
tion may be an effective, less invasive, and safe treatment for
patients with inoperable TIO [99]. However, long-term effica-
cy of these modalities has not been demonstrated.
Octreotide is an alternative medical therapy that may be
used, but not all patients respond to this treatment, possibly
due to inter-individual differences in tumor somatostatin re-
ceptor expression [66].
Treatment with cinacalcet could also be effective for the
treatment of TIO patients to decrease phosphaturia, reduce
the need for phosphate and calcitriol supplements, and bring
about bone healing [100]. In two TIO patients, cinacalcet im-
proved long-term phosphate concentrations while the doses of
calcitriol and phosphate were decreased [100]. In addition,
calcitonin was used in a patient with TIO, decreasing serum
FGF-23 levels [101]. However, further studies are needed.
Finally, preliminary evidence shows that KRN23 treatment
increases serum phosphate and 1,25(OH)2D3 levels, also in
patients affected by TIO [102]. These findings show that
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KRN23 will potentially be an effective treatment in cases that
cannot be cured easily with surgery [96, 103].
Current care of hereditary hypophosphatemic rickets
with hypercalciuria
Due to preexisting hypercalciuria, patients with HHRH must
not be treated with vitamin D in order to prevent severe
nephrocalcinosis and should receive only phosphate supple-
mentation. Phosphate dosage based on elemental phosphorus
is usually in the range of 1–2.5 g, given in four to five divided
doses daily in adults and older children (20–50 mg/kg of ele-
mental phosphorus per day). The aim is to decrease the high
1,25(OH)2D3 levels in order to reduce intestinal calcium ab-
sorption and to increase the phosphate supply, enhancing and
maintaining bone mineralization. Moreover, avoidance of a
high sodium diet is recommended [30].
Current care of fibrous dysplasia
and McCune-Albright syndrome
The therapeutic management of hypophosphatemia is the
same as in other FGF23-mediated phosphate wasting diseases,
including the use of phosphate and active vitamin D [104]. So
far, there are no controlled studies to support that treating
hypophosphatemia improves bone pain or decreases bone
fractures; however, observations of treated patients affected
by FD/MAS suggest that this treatment may improve out-
comes [104].
Conclusions
Knowledge concerning mechanisms and processes involved
in phosphate wasting disorders has greatly increased in the last
decade, especially by the demonstration of the central role of
the factor FGF-23 derived by bone.
Pharmacological management requires an adequate bal-
ance between the benefits derived from treatment itself with
complicated and long-term monitoring and the potential risks,
and these differ over the lifetime. Involving clinicians with
experience in treating these disorders is considered fundamen-
tal to the successful management of these patients. Currently,
pharmacological conventional treatment of these disorders of-
fers limited efficacy and is potentially associated to gastroin-
testinal, renal, and parathyroid complications, compromising
the patient’s quality of life.
Attempts to modify FGF-23 activity are certainly a funda-
mental point in the treatment of these diseases, also because, as
already described, FGF-23 has several extraskeletal actions.
Recent studies and trials have shown that FGF-23 blockade
through neutralizing antibodies offers a new possible treatment
for patients affected by XLH and may open new therapeutic
choices for other FGF-23-related disorders of renal phosphate
wasting and bone mineralization defects. Moreover, long-term
studies on the use of drugs that reduce FGF-23 levels could
clarify whether some clinical complications, such as
enthesopathy and dental abscesses, are mediated in part by
FGF-23 itself or by low phosphorus levels or other factors.
In the future, other agents able to decrease FGF-23 expres-
sion or its activity, or modulate renal transporters, may open
the way for other successful and effective therapeutic alterna-
tives for these disorders. These pharmacological efforts may
lead to greater clinical efficacy, reduction of side effects, and
improvement in terms of quality of life for these patients.
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